

Department of Internal Medicine

Division of Clinical Oncology/Hematology

Keisuke Aiba, *Professor*
Takaki Shimada, *Associate Professor*
Hidekazu Masuoka, *Assistant Professor*
Shingo Yano, *Assistant Professor*
Yoji Ogasawara, *Assistant Professor*
Takeshi Saito, *Assistant Professor*

Noriko Usui, *Appointed Professor*
Nobuaki Dobashi, *Associate Professor*
Kaichi Nishiwaki, *Assistant Professor*
Yuhichi Yahagi, *Assistant Professor*
Katsuki Sugiyama, *Assistant Professor*
Yuko Shiota, *Assistant Professor*

General Summary

The immediate goals of our clinical and basic research are to investigate basic and clinical aspects of malignant diseases and to try to improve outcomes for patients with solid tumors and hematological malignancies, leading to the ultimate goals of improving the natural history of malignant diseases. We have also been performing several clinical trials and basic research studies successfully throughout 2016.

Research Activities

Leukemias

Many patients with previously untreated hematological disorders have been referred to our department. The disorders in 2016 included acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), 24 cases and chronic myeloid leukemia (CML), 4 cases. We have performed clinical trials as a member of the Japan Adult Leukemia Study Group (JALSG), which is a distinguished leukemia research group established more than 20 years ago in Japan for clinical research and treatment of AML, ALL, and CML.

Lymphomas

In 2016 we registered 67 patients with newly diagnosed non-Hodgkin's lymphoma. We have performed clinical trials as a member of the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG). The study JCOG0601 (newly diagnosed low risk advanced diffuse large B cell lymphoma: phase II/III) was pivotal protocol studies beginning in 2007.

Myeloma

We registered 9 patients with newly diagnosed multiple myeloma in 2016. A novel agent, the proteasome inhibitor bortezomib, became available in 2007, and we have used it with or without dexamethasone to treat patients who had refractory myeloma.

In-house protocols are also under investigation. A phase II study of CVD regimen (cyclo phosphamide+bortezomib+dexamethasone) for patients with newly diagnosed multiple myeloma.

Hematopoietic stem cell transplantation

To investigate and establish safer and more effective hematopoietic stem cell transplantation (HSCT), we have performed serial clinical studies examining umbilical cord blood transplantation, reduced-intensity stem cell transplantation from haploidentical donor, and investigation of mechanisms of graft-versus-host disease in HSCT.

Solid tumors

Many patients with solid cancers have been referred to our department from related divisions or departments from both inside and outside our hospital. Several of our studies seeking improved therapeutic outcomes are in progress throughout our university hospital with related divisions or departments. Since late 2008 we have been investigating a combined-modality therapy of radiation and chemotherapy with docetaxel, cisplatin, and 24 hours' continuous infusion of 5-FU (DCF regimen) for patients with locally advanced esophageal cancer. The study has been completed and the results have published recently. Successively an improved protocol was launched 3 years ago and now has been investigating. We performed a novel drug-development study with an orally decaying formulation of S-1 co-operating with a colleague department had completed in patients with advanced gastric cancer and the new formulation of S-1 became now available in daily practice. Our first-line chemotherapies for patients with advanced colorectal cancer are folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and folinic acid, 5-FU, and irinotecan (FOLFIRI). Since antibodies against vascular endothelial growth factor (VEGF) and against epidermal growth factor receptor (EGFR) became available in 2007 and 2008, respectively, combination therapies of these antibodies and FOLFOX or FOLFIRI have also been performed. Since oral drugs are more convenient and safer, 5-FU is replaced by S-1 or capecitabine in such i.v. combination chemotherapy as FOLFOX or FOLFIRI, leading to develop improved regimens of SOX, XELOX, IRIS and XELIRI. Salvage therapies using regorafenib or TAS-102 became standard care for resistant and refractory advanced colorectal cancer.

Basic research

One of our important activities is translational research on solid cancers and hematological malignancies. Since clinical requirement is urgent, persistent research is warranted. Cancer fatigue is now an emerging issue for patients with advanced malignant disease. We have been evaluating the correlation between cancer fatigue and human herpesvirus 6 (HHV-6) reactivation using patient's salivary juice and blood samples, collaborating with the department of Virology. The preliminary result was reported at the annual meeting of the Multinational Association of Supportive Care in Cancer (MASCC) in Miami, Florida (USA).

Life-threatening disease, such a study seems to be highly of great consequence. Supportive care in cancer is also very important for patients with malignant disease. We have been working on such a field for years. Measuring L-FABP level in patient's urine can predict renal damage caused by cisplatin. Therefore, we have been trying to see if L-FABP is worth enough to measure for early detection of renal damage in patients undergoing cisplatin combination chemotherapy such as DCF and GDP. The studies are

vigorously in progress.

Publications

- Aoki J, Seo S, Kanamori H, Tanaka M, Fukuda T, Onizuka M, Kobayashi N, Kondo T, Sawa M, Uchida N, Iwato K, Ichinohe T, Atsuta Y, Yano S, Takami A.** Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML. *Bone Marrow Transplant.* 2016; **51**: 604-6.
- Aoki J, Kanamori H, Tanaka M, Yamasaki S, Fukuda T, Ogawa H, Iwato K, Ohashi K, Okumura H, Onizuka M, Maesako Y, Teshima T, Kobayashi N, Morishima Y, Hirokawa M, Atsuta Y, Yano S, Takami A.** Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. *Am J Hematol.* 2016; **91**: 302-7.
- Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Wakita S, Kanamori H, Usuki K, Uoshima N, Yanada M, Shono K, Ueki T, Mizuno I, Yano S, Takeuchi J, Kanda J, Okamura H, Inamoto Y, Inokuchi K, Fukuda T.** Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha. *Biol Blood Marrow Transplant.* 2016; **22**: 1125-32.
- Yanada M, Yano S, Kanamori H, Gotoh M, Emi N, Watakabe K, Kurokawa M, Nishikawa A, Mori T, Tomita N, Murata M, Hashimoto H, Henzan H, Kanda Y, Sawa M, Kohno A, Atsuta Y, Ichinohe T, Takami A.** Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. *Leuk Lymphoma.* 2017; **58**: 1061-7.
- Suzuki K, Yano S, Nishiwaki K, Sano K, Shimada T, Yahagi Y, Ogasawara Y, Sugiyama K, Takahara S, Saito T, Kasama K, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Masuoka H, Katori M, Machishima T, Ouchi A, Dobashi N, Kaito K, Usui N, Aiba K.** Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. *Cancer Med.* 2016; **5**: 3051-8.
- Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.** Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. *Oncol Rep.* 2016; **36**: 2976-82.
- Takagi S, Masuoka K, Uchida N, Kurokawa M, Nakamae H, Imada K, Iwato K, Ichinohe T, Atsuta Y, Takami A, Yano S.** Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2016; **22**: 2208-13.
- Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S.** Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. *Ann Hematol.* 2017; **96**: 289-97.
- Konuma T, Kondo T, Yamashita T, Uchida N, Fukuda T, Ozawa Y, Ohashi K, Ogawa H, Kato C, Takahashi S, Kanamori H, Eto T, Nakaseko C, Kohno A, Ichinohe T, Atsuta Y, Takami A, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).** Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. *Ann Hematol.* 2017; **96**: 469-78.
- Yanada M, Kurosawa S, Kobayashi T, Ozawa Y, Kanamori H, Kobayashi N, Sawa M, Nakamae H, Uchida N, Hashimoto H, Fukuda T, Hirokawa M, Atsuta Y, Yano S.** Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study. *Bone Marrow Transplant.* 2017 Jun; **52**: 818-24. Epub 2017 Jan 23.
- Mashima K, Yano S, Yokoyama H, Saito T, Machishima T, Shimada T, Yahagi Y, Takahara S, Sugiyama K, Ogasawara Y, Minami J, Kamiyama Y, Katsube A, Suzuki K, Ohshima S, Yamada H, Usui N, Aiba K.** Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature Review. *Intern Med.* 2017; **56**: 701-6.
- Hayashi K, Nagasaki E, Kan S, Ito M, Kamata Y, Homma S, Aiba K.** Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. *Cancer Sci.* 2016; **107**: 682-9.
- Shirai Y, Shiba H, Iwase R, Haruki K, Fujiwara Y, Furukawa K, Uwagawa T, Ohashi T, Yanaga K.** Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. *Cancer Lett.* 2016;

370: 177-84.

Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, Bernhardt M, Ghadimi BM, Gaida MM, Bergmann F, Werner J, Ried T, Hanna N, Alexander HR, Hussain SP. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. *Cancer Res.* 2016; **76**: 3838-50.

Horiuchi T, Uwagawa T, Shirai Y, Saito N, Iwase R, Haruki K, Shiba H, Ohashi T, Yanaga K. New treatment strategy with nuclear factor- κ B inhibitor for pancreatic cancer. *J Surg Res.* 2016; **206**: 1-8.

Fukushima R, Kobayashi Y, Fukuhara S, Miyamoto K, Munakata W, Maruyama D, Kim SW, Watanabe T, Taniguchi H, Maeshima A, Tobinai K. A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma. *J Chemother.* 2016; **28**: 116-22.

Ishii H, Konuma T, Kato S, Oiwa-Monna M, Tojo A, Takahashi S. Impact of hematogones on the long-term outcomes of single-unit cord blood transplantation for adult patients. *Leuk Lym-*

phoma. 2017; **58**: 118-126.

Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, Morita Y, Nishiwaki K, Ninomiya H, Gotoh A, Imashuku S, Urabe A, Shichishima T, Nishimura J, Kanakura Y. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. *Int J Hematol.* 2016; **103**: 703-12.

Kawamura K, Ikeda T, Hagiwara S, Mori T, Shinagawa A, Nishiwaki K, Ohashi K, Kubonishi S, Fukuda T, Ito T, Tomita N, Ichinohe T, Kato K, Morishima Y, Atsuta Y, Sunami K, Kanda Y. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. *Leuk Lymphoma.* 2016; **57**: 2077-83.

Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, Shichishima T, Okamoto S, Nishimura JI, Ohyashiki K, Nakao S, Ando K, Kanda Y, Kawaguchi T, Nakakuma H, Harada D, Akiyama H, Kinoshita T, Ozawa K, Omine M, Kanakura Y. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. *Int J Hematol.* 2016; **104**: 548-58.